Tenax Therapeutics (NASDAQ:TENX) Stock Passes Above Two Hundred Day Moving Average – Should You Sell?

Tenax Therapeutics, Inc. (NASDAQ:TENX) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $4.05 and traded as high as $5.67. Tenax Therapeutics shares last traded at $5.49, with a volume of 4,397 shares trading hands.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. William Blair began coverage on shares of Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating on the stock. Guggenheim started coverage on shares of Tenax Therapeutics in a research note on Monday, October 14th. They set a “buy” rating and a $16.00 price target on the stock. Leerink Partnrs upgraded shares of Tenax Therapeutics to a “strong-buy” rating in a report on Thursday, October 24th. Leerink Partners assumed coverage on Tenax Therapeutics in a research note on Thursday, October 24th. They issued an “outperform” rating and a $16.00 price objective on the stock. Finally, StockNews.com started coverage on shares of Tenax Therapeutics in a research report on Thursday, September 26th. They set a “sell” rating for the company. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Up 2.9 %

The firm’s 50 day moving average price is $5.07 and its two-hundred day moving average price is $4.06.

Hedge Funds Weigh In On Tenax Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. purchased a new position in shares of Tenax Therapeutics during the 3rd quarter valued at approximately $101,000. Stonepine Capital Management LLC bought a new position in Tenax Therapeutics during the 3rd quarter valued at $173,000. Finally, Vestal Point Capital LP bought a new position in Tenax Therapeutics during the 3rd quarter valued at $288,000. 1.67% of the stock is owned by hedge funds and other institutional investors.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.